uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
October 31, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
October 28, 2019 07:00 ET
|
uniQure Inc.
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of...
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
September 03, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences
July 26, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
July 06, 2019 07:00 ET
|
uniQure Inc.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
June 21, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
May 10, 2019 08:00 ET
|
uniQure Inc.
~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported...
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
February 28, 2019 07:00 ET
|
uniQure Inc.
~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX Activity at up to 51% of...
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
February 08, 2019 07:00 ET
|
uniQure Inc.
~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor Infusions, Reported Bleeding...
uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
February 04, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...